EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Obsessive-Compulsive Disorder - Pipeline Review, H1 2017

  • ID: 4091096
  • Report
  • February 2017
  • 36 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc
  • Omeros Corp
  • Savant HWP Inc
  • MORE
Obsessive-Compulsive Disorder - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H1 2017, provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Preclinical and Discovery stages are 1, 7 and 1 respectively.

Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obsessive-Compulsive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc
  • Omeros Corp
  • Savant HWP Inc
  • MORE
Introduction

Obsessive-Compulsive Disorder - Overview

Obsessive-Compulsive Disorder - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Obsessive-Compulsive Disorder - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Amorsa Therapeutics Inc

C4X Discovery Holdings PLC

Omeros Corp

Savant HWP Inc

Obsessive-Compulsive Disorder - Drug Profiles

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-88178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluvoxamine maleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HUF-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Obsessive-Compulsive Disorder - Dormant Projects

Obsessive-Compulsive Disorder - Discontinued Products

Obsessive-Compulsive Disorder - Product Development Milestones

Featured News & Press Releases

Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction

Aug 02, 2007: Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Obsessive-Compulsive Disorder, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc, H1

Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H1

Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc, H1

Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Holdings PLC, H1

Obsessive-Compulsive Disorder - Pipeline by Omeros Corp, H1

Obsessive-Compulsive Disorder - Pipeline by Savant HWP Inc, H1

Obsessive-Compulsive Disorder - Dormant Projects, H1

Obsessive-Compulsive Disorder - Discontinued Products, H1

List of Figures:

Number of Products under Development for Obsessive-Compulsive Disorder, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc
  • C4X Discovery Holdings PLC
  • Omeros Corp
  • Savant HWP Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll